MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

Search

Abeona Therapeutics Inc

Closed

5.38 0.56

Overview

Share price change

24h

Current

Min

5.21

Max

5.5

Key metrics

By Trading Economics

P/E

Sector Avg

8.109

37.257

Employees

136

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+269.69% upside

Dividends

By Dow Jones

Next Earnings

12 Nov 2025

Market Stats

By TradingEconomics

Market Cap

-43M

234M

Previous open

4.82

Previous close

5.38

Abeona Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

13 Oct 2025, 21:45 UTC

Acquisitions, Mergers, Takeovers

Goldman Sachs to Acquire Industry Ventures for Up to $965 Million -- Update

13 Oct 2025, 21:07 UTC

Acquisitions, Mergers, Takeovers

Goldman Sachs to Acquire Industry Ventures for Up to $965 Million

13 Oct 2025, 17:03 UTC

Major Market Movers

Canaan ADRs Climb on Launch of Gas-to-Computing Pilot in Canada

13 Oct 2025, 23:53 UTC

Market Talk

Gold Rises, Buoyed by Bullish Fundamental Backdrop -- Market Talk

13 Oct 2025, 23:39 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

13 Oct 2025, 22:15 UTC

Market Talk

Global Equities Roundup: Market Talk

13 Oct 2025, 22:15 UTC

Market Talk

Precinct Properties NZ's Equity Raising Looks Opportunistic -- Market Talk

13 Oct 2025, 21:57 UTC

Acquisitions, Mergers, Takeovers

Goldman Buys $7B Venture-Capital Firm in Latest Asset-Management Bet -- Barrons.com

13 Oct 2025, 21:36 UTC

Market Talk

Global Equities Roundup: Market Talk

13 Oct 2025, 21:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13 Oct 2025, 21:36 UTC

Market Talk

Fletcher's Near-Term Headwinds Don't Cloud Earnings Opportunity -- Market Talk

13 Oct 2025, 21:30 UTC

Acquisitions, Mergers, Takeovers

Goldman Sachs to Acquire Industry Ventures for Up to $965M -- Update

13 Oct 2025, 21:06 UTC

Acquisitions, Mergers, Takeovers

Goldman Buys $7B Venture-Capital Firm in Latest Asset-Management Bet -- Barrons.com

13 Oct 2025, 20:52 UTC

Acquisitions, Mergers, Takeovers

Goldman Sachs to Acquire Industry Ventures for Up to $965M

13 Oct 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

13 Oct 2025, 20:35 UTC

Acquisitions, Mergers, Takeovers

Goldman Expects to Close Deal in 1Q

13 Oct 2025, 20:34 UTC

Acquisitions, Mergers, Takeovers

Industry Ventures Will Be Part of Goldman's External Manager Platform, External Investing Group

13 Oct 2025, 20:33 UTC

Acquisitions, Mergers, Takeovers

Industry Ventures Currently Manages $7B of Assets Under Supervision

13 Oct 2025, 20:32 UTC

Acquisitions, Mergers, Takeovers

Goldman Sachs: Deal to Include Up to $300M of Additional Contingent Consideration Based on Future Performance Through 2030

13 Oct 2025, 20:31 UTC

Acquisitions, Mergers, Takeovers

Goldman Sachs: Consideration to Include $665M Cash and Equity Payable at Closing

13 Oct 2025, 20:29 UTC

Acquisitions, Mergers, Takeovers

Goldman Sachs to Buy VC Firm Industry Ventures

13 Oct 2025, 19:05 UTC

Market Talk

Oil Futures Pick Up on Easing U.S.-China Tension -- Market Talk

13 Oct 2025, 18:59 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

13 Oct 2025, 18:26 UTC

Market Talk

Precious Metals Close at New Record Highs -- Market Talk

13 Oct 2025, 18:10 UTC

Market Talk

Global Equities Roundup: Market Talk

13 Oct 2025, 18:10 UTC

Market Talk

Broadcom's OpenAI Deal Highlights AI Opportunity -- Market Talk

13 Oct 2025, 17:05 UTC

Market Talk

Global Equities Roundup: Market Talk

13 Oct 2025, 17:05 UTC

Market Talk

OpenAI Deal Offers Huge Upside to Broadcom's Earnings -- Market Talk

13 Oct 2025, 16:03 UTC

Acquisitions, Mergers, Takeovers

Umicore Completes Sale, Subsequent Lease-in of Permanent Gold Inventories

13 Oct 2025, 15:35 UTC

Market Talk

Precious Metals Push Record Highs Further -- Market Talk

Peer Comparison

Price change

Abeona Therapeutics Inc Forecast

Price Target

By TipRanks

269.69% upside

12 Months Forecast

Average 20 USD  269.69%

High 20 USD

Low 20 USD

Based on 2 Wall Street analysts offering 12 month price targets forAbeona Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

2

Buy

0

Hold

0

Sell

Financials

$

About Abeona Therapeutics Inc

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.
help-icon Live chat